The effects of selective serotonin reuptake inhibitors and their metabolites on S‐mephenytoin 4'‐hydroxylase activity in human liver microsomes.

British Journal of Clinical Pharmacology

Volumn 40, Issue 5, 1995, Pages 481-485

  Kobayashi, K ^a   Yamamoto, T ^a   Chiba, K ^a   Tani, M ^a   Ishizaki, T ^a   Kuroiwa, Y ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DEMETHYLCITALOPRAM; DIDEMETHYLCITALOPRAM; DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL;

CITALOPRAM; COMPARATIVE STUDY; CYTOCHROME P-450 ENZYME SYSTEM; FLUOXETINE; HUMAN; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SUPPORT, NON-U.S. GOV'T;

EID: 0028842707     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1995.tb05793.x     Document Type: Article

References (33)

1. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
2. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessivecompulsive disorder
3. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
4. A review of the metabolism and pharmacokinetics of paroxetine in man
5. Clinical implications of the pharmacology of sertraline
6. High‐performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients
7. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin
8. The effects of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
9. Inhibitors of imipramine metabolism by human liver microsomes
10. The relationship between paroxetine and the sparteine oxidation polymorphism
11. Defective N‐oxidation of sparteine in man: a new pharmacogenetic defect
12. A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population
13. Steady‐state concent rations of imipramineand itsmetabolites inrelation to the sparteine/debrisoquine polymorphism
14. The debrisoquine hydroxylation test predicts steady‐state plasmalevels of desipramine
15. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
16. E‐and Z‐10‐hydroxylation of nortriptyline: relationship to polymorphic debrisoquin hydroxylation
17. Themephenytoin oxidation polymorphism is partially responsible for the N‐demethylation ofimipramine
18. Metabolic disposition of imipramine in Oriental subjects: Relation to metoprolol −‐hydroxylation and S‐mephenytoin 4′‐hydroxylation phenotypes
19. The role of S‐mephenytoin 4′‐hydroxylase in imipramine metabolism by human liver microsomes: A two‐enzyme kinetic analysis of N‐demethylation and 2‐hydroxylation
20. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P‐450 isozymes
21. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphism
22. In vitro inhibition studies of two isozymes of human liver cytochrome P‐450. Mephenytoin p‐hydroxylase and sparteine monooxygenase
23. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P‐450 human‐2
24. Development and preliminary application of a simple assay of S‐mephenytoin 4‐hydroxylase in human liver microsomes
25. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S‐mephenytoin 4′‐hydroxylation
26. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
27. Characterization and inhibition of mephenytoin 4‐hydroxylation activity in human liver microsomes
28. Stereoselective metabolism of mephobarbital in relation to the polymorphic oxidation of S‐mephenytoin in humans
29. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7‐ethoxycoumarin in vitro
30. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype
31. Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
32. m diazepam N‐demethylase in livers of poor metabolizers for S‐mephenytoin 4′‐hydroxylation
33. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam